In recent decades, researchers have studied the role of the BARD1 (BRCA1-associated RING domain 1) gene in cancer progression and its usage as a prognostic biomarker for cancer and a potential candidate for targeted cancer therapy [1]. This evidence concerns the gene BARD1 and cancer.